Wall Street analyst estimates for Rocket Pharmaceuticals, Inc. (RCKT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.39 | ||
| 2026-08-10 | $1.08 | $0.86 | +25.6% |
| 2026-05-07 | $-0.42 | $-0.41 | -2.4% |
| 2026-02-26 | $-0.38 | $-0.42 | +9.5% |
| 2025-11-06 | $-0.45 | $-0.48 | +6.2% |
| 2025-08-07 | $-0.59 | $-0.57 | -3.5% |
| 2025-05-08 | $-0.56 | $-0.59 | +5.1% |
| 2025-02-27 | $-0.62 | $-0.68 | +8.8% |
Valuation Ratios
| Price / Book | 1.02 |
| EV / EBITDA | 20.89 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $169000 | $204000 | $330000 | $426000 | $1.1M | 0 | 0 | 0 | 0 | $11.0M |
| Gross Profit | -$169000 | -$204000 | -$330000 | -$426000 | -$1.1M | 0 | 0 | 0 | 0 | -$11.0M |
| Research & Development | $32.0M | $14.2M | $53.3M | $58.6M | $106.4M | $125.5M | $165.6M | $186.3M | $171.2M | $142.0M |
| Selling, General & Admin | $9.9M | $12.5M | $17.9M | $17.5M | $27.9M | $41.8M | $58.8M | $73.3M | $102.0M | $86.5M |
| Operating Expenses | $41.9M | $26.7M | $71.0M | $75.9M | $134.9M | $167.2M | $224.3M | $259.7M | $273.2M | $217.5M |
| Operating Income | -$41.9M | -$26.7M | -$71.2M | -$76.2M | -$136.0M | -$167.2M | -$224.3M | -$259.7M | -$273.2M | -$228.5M |
| EBITDA | -$41.3M | -$26.7M | -$71.2M | -$71.1M | -$131.6M | -$157.8M | -$213.7M | -$236.6M | -$247.5M | -$210.2M |
| Interest Expense | $1.4M | $3.6M | $5.2M | $4.8M | $7.5M | $5.9M | $1.9M | $1.9M | $1.9M | $1.9M |
| Pre-tax Income | -$42.9M | -$29.5M | -$74.5M | -$77.3M | -$139.7M | -$169.1M | -$221.9M | -$245.6M | -$258.7M | -$223.1M |
| Income Tax | 0 | 0 | 0 | 0 | $7.0M | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$42.9M | -$29.5M | -$74.5M | -$83.2M | -$146.7M | -$169.1M | -$221.9M | -$245.6M | -$258.7M | -$223.1M |
| EPS | $-6.41 | $-4.36 | $-1.89 | $-1.70 | $-2.52 | $-2.68 | $-3.26 | $-2.92 | $-2.73 | $-2.01 |
| EPS (Diluted) | $-6.41 | $-4.36 | $-1.89 | $-1.70 | $-2.52 | $-2.68 | $-3.26 | $-2.92 | $-2.73 | $-2.01 |
| Shares Outstanding (Diluted) | $6.7M | $6.8M | $39.4M | $49.0M | $55.4M | $63.2M | $68.1M | $84.0M | $94.8M | $111.1M |
Price
| Price | $3.48 |
| Market Cap | $380M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANNX · AURA · AUTL · DBVT · DSGN · GALT · IMAB
Explore sector: Healthcare · Biotechnology
More sections of RCKT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks